Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DESCARTES-33
- Development stage
- Preclinical
- Lead developer
- Cartesian Therapeutics
- Modality
- Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Parenteral
01
Overview
DESCARTES-33 is an off-the-shelf, allogeneic, RNA-engineered mesenchymal stem cell (MSC) therapy being developed by Cartesian Therapeutics, leveraging its proprietary RNA Armory platform. This therapy is being investigated as a treatment for autoimmune diseases. The RNA engineering of the MSCs is designed to enable targeted immunomodulation for disease processes in autoimmune conditions. As of the latest public information, DESCARTES-33 is in preclinical development.
- Brand names
- DESCARTES-33DESCARTES33DESCARTES 33
- Other names
- DESCARTES-33DESCARTES33DESCARTES 33
Beyond the preview
Go deeper on DESCARTES-33.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DESCARTES-33.